Skip to content
OpenCapital
Get started

TScan Therapeutics, Inc. TCRX Q4 2024 Annual earnings

Reported March 5, 2025 · Before market open

Revenue$665.0KMiss by $854.8K
EPS-$0.29Miss by $0.02
Revenue estimate$1.5M
EPS estimate-$0.27

Next report

Aug 11, 2026 (In 1 week)
Revenue estimate$1.9M
EPS estimate-$0.29

Versus estimates

Revenue

Q1 2026$982.0KMiss by $1.5MQ4 2025$2.6MBeat by $131.5KQ3 2025$2.5MBeat by $571.0KQ2 2025$3.1MBeat by $1.2MQ1 2025$2.2MBeat by $1.1M
Q4 2024$665.0KMiss by $854.8K

Diluted EPS

Q1 2026-$0.22In lineQ4 2025-$0.18Beat by $0.09Q3 2025-$0.28Beat by $0.07Q2 2025-$0.28In lineQ1 2025-$0.26Beat by $0.02
Q4 2024-$0.29Miss by $0.02

Ask the moment TScan Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did TScan Therapeutics, Inc. report Q4 2024 earnings?
TScan Therapeutics, Inc. (TCRX) reported Q4 2024 earnings on March 5, 2025 before market open.
What were TScan Therapeutics, Inc.'s Q4 2024 revenue and EPS?
TScan Therapeutics, Inc. reported revenue of $665.0K and eps of $-0.29 for Q4 2024.
Did TScan Therapeutics, Inc. beat estimates in Q4 2024?
Revenue missed the consensus estimate of $1.5M by $854.8K. EPS missed the consensus estimate of $-0.27 by $0.02.
Where can I find TScan Therapeutics, Inc.'s Q4 2024 SEC filings?
You can read the 10-K periodic report (0000950170-25-033077) directly on SEC EDGAR. The filing index links above go to sec.gov.